Hikma Pharmaceuticals Public annual current ratio
2020
2021
2022
2023
2024
2025
Hikma Pharmaceuticals Public Current Ratio Growth & History (HIK)
Hikma Pharmaceuticals Public's current ratio was 1.82 for fiscal 2025.
View full Hikma Pharmaceuticals Public company overviewHikma Pharmaceuticals Public annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.82 | 0.67 | +58.99% |
| 2024 | 2024-12-31 | 1.14 | −0.42 | −27.05% |
| 2023 | 2023-12-31 | 1.57 | −0.29 | −15.50% |
| 2022 | 2022-12-31 | 1.86 | −0.20 | −9.94% |
| 2021 | 2021-12-31 | 2.06 | 0.19 | +10.24% |
| 2020 | 2020-12-31 | 1.87 | — | — |
Hikma Pharmaceuticals Public quarterly current ratio
Q4.24
Q4.25
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 1.98 | — | — |
| Q4 2025 | 2025-12-31 | 1.82 | 0.67 | +58.99% |
| Q4 2024 | 2024-12-31 | 1.14 | — | — |
Hikma Pharmaceuticals Public current ratio trends
Over the last five fiscal years, Hikma Pharmaceuticals Public's current ratio decreased from 1.87 to 1.82, a change of −0.05. The latest reported quarter, Q2 2026, shows 1.98.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as reported current assets divided by reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hikma Pharmaceuticals Public source filings ↗Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...